Slides
Page 1
0 156 256 255 255 250 0 0 0 154 154 154 219 254 0 233 233 233 Titles & Subtitles: Bai Jamjuree Medium (Headings) Text: Bai Jamjuree Medium Bold text: Bai Jamjuree Bold 191 255 255 A quarter with strong sales and profitability - We continue to deliver on our strategy Edvard Kälvesten, President and CEO Maria Engström, CFO Silex Interim Report July - September 2026
Page 2
Disclaimer This presentation may contain forward-looking statements which reflect Silex Microsystems AB’s current view on future events and financial and operational development. Words such as “intend”, “expect”, “anticipate”, “may”, “believe”, “plan”, “estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forwardlooking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements. Silex Interim Report July - Sept 2026 1
Page 3
Silex Interim Report July - Sept 2026 2 Q3 2026 Highlights ▪ Strong sales and profitability in Q3. ▪ 21.7 percent sales growth Y-o-Y and an EBIT margin of 35.8 percent. ▪ The ownership change, IPO and the on-going establishment of U.S. manufacturing have helped secure a significant number of development contracts and enhanced commercial opportunities mainly within Telecom, including OCS, and Life Science, including Medical Imaging. ▪ On July 7, Silex entered into a definitive agreement to acquire a semiconductor facility in Pennsylvania, USA, establishing manufacturing capacity in the U.S. ▪ Planning ongoing for the conversion of the fab into a MEMS fab. ▪ Product qualification activities ongoing for MEMS devices to be manufactured at the fab. ▪ Expansion in Järfälla, Sweden, continuing as planned. New cleanroom expansion ongoing.
Page 4
Silex – the first choice for some of the world’s greatest innovators HQ Sales representatives Swedish heritage, global mindset Pure-play MEMS foundry Broad range of MEMS capabilities and technologies 1. 2. 3. 4. World’s leading firms rely on Silex to power their innovations #1 Global MEMS foundry ~ 535 Employees of which ~ 225 engineers 16.5% Growth LTM Sept 2026 SEKm 1 584 Net sales LTM Q3 26 33.2% EBIT margin LTM Q3 26 SEKm 546 CF from op. activities incl. WC LTM Q3 26 LTM Q3 26 Silex Interim Report July - Sept 2026 3 U.S fab 59% 29% 11% 1% North America Europe Asia Pacific RoW
Page 5
MEMS exists in all modern devices and applications across industries What is MEMS? ▪ MEMS technology leverages IC semiconductor manufacturing processes to integrate both mechanical and electrical functions on a single chip. ▪ Enables physical sensing and micro-actuation, allowing microscopic semiconductor chips to detect and respond to various physical conditions. ▪ Components are typically fabricated on silicon or glass substrates. ▪ Silex's vision is to become to MEMS foundries what TSMC is to IC foundries: a clear leading manufacturer and a go-to-foundry for the global leading tech companies’ most advanced designs. Telecoms Optical transceivers Optical switching Silicon photonics RF filters Consumer Inertial measurement units Audio MEMS Image stabilisation Micro LED Industrial Timing devices Micro-mirror devices Robotics Pressure & flow sensors Automotives Airbags Tire pressure monitoring Thermal imaging Autonomous driving DNA analysis Medical sensors & implantables Drug delivery Medical imaging Life Science & Medical Provides the ‘pick and shovel’ wherever the physical world is translated into digital MEMS stands for “Micro Electromechanical Systems” Silex Interim Report July - Sept 2026 4
Page 6
Q3 2026 Key figures Net Sales Q3, SEKm 413 21.7% growth YoY EBIT Q3, SEKm 148 35.8% margin Cash Flow from operating activities Q3, SEKm 145 LTM SEKm 546 ▪ Currency adjusted growth 22.0% (43.9). ▪ Sales growth was driven by higher sales from both development and production projects, with strong growth in the end-market for Life Science and Medical Technology, as well as for optical switches and AI in the Telecoms end- market. ▪ Strong EBIT driven by sales growth exceeding cost increases, supported by our scalable business model and a positive FX impact of SEKm 12 (-7m). ▪ Strong operating cash flow supported by higher operating profit and improved working capital development. Silex Interim Report July - Sept 2026 5 1 Alternative Performance Measures (“APM”). Definitions are available in the interim report.
Page 7
138 182 201 231 339 413 Q3 25 Q3 26 99 90 109 183 88 6644 73 339 413 Q3 25 Q3 26 100 106 38 49 189 253 12 4339 413 Q3 25 Q3 26 Net sales Per geography Per end market Per product category Industrials & Automotive Telecoms Life Science & Medical ConsumerEurope Asia North America RoW Development Production SEKm SEKmSEKm Silex Interim Report July - Sept 2026 6 ▪ North America remained the key growth driver, reinforcing the strategic importance of our US fab acquisition. ▪ Strong growth in Telecoms, driven by AI and OCS demand, alongside continued growth in Life Science and Medical Technology. ▪ Growth was driven by both development and production projects, with continued strong demand from new and existing customers.
Page 8
Market update Q3 2026 Silex Interim Report July - Sept 2026 7 U.S. Fab Expansion – Unlocking customer opportunities The announced U.S. manufacturing expansion has generated increased customer interest, particularly from North American companies seeking domestic MEMS manufacturing. The dual-continent footprint strengthens Silex's attractiveness for strategic, long-term manufacturing partnerships. Life Science & Medical – Strong growth momentum Increasing customer demand in medical imaging, advanced diagnostics and biosensing is reinforcing Life Science & Medical as a key growth driver for Silex, with opportunities spanning both existing customers and new development programs. Defense & Aerospace – Growing transatlantic traction Silex is experiencing increased engagement from defense and aerospace customers in both the U.S. and Europe. Demand for trusted supply chains, advanced sensing technologies and specialized MEMS manufacturing is creating new business opportunities.
Page 9
Expansion initiatives Silex Interim Report July - Sept 2026 8 United States ▪ Definitive agreement signed to acquire a 200 mm integrated circuit fab in Pennsylvania, establishing U.S. manufacturing footprint for Silex. ▪ Acquisition supports future growth with significant expansion potential and planned conversion to MEMS production. Järfälla, Sweden ▪ Järfälla cleanroom expansion progressing according to plan, with approximately 35% additional production capacity (500 sqm cleanroom, 80 office desks). ▪ Construction under way ▪ Production start Q2, 2027
Page 10
0 156 256 255 255 250 0 0 0 154 154 154 219 254 0 233 233 233 Titles & Subtitles: Bai Jamjuree Medium (Headings) Text: Bai Jamjuree Medium Bold text: Bai Jamjuree Bold 191 255 255 Silex acquires semiconductor fab in Mountain Top, Pennsylvania U.S. IC Fab, Mountain Top, Pennsylvania ▪ Signed a definitive agreement to acquire a 200 mm integrated circuit fab in Mountain Top, Pennsylvania, from Onsemi. ▪ Follows the non-binding letter of intent previously disclosed in Silex’s Prospectus. ▪ Structured as an asset purchase and includes the production facility, real property, infrastructure and manufacturing equipment. ▪ Purchase price: USDm 40 (USDm 10 at signing, USDm 30 at closing). ▪ Closing: Expected around year-end 2027, enabling Silex to stepwise build up MEMS capacity and capabilities, while Onsemi ramps down their legacy products. Closing is subject to customary conditions and approval from the Committee on Foreign Investment in the United States (CFIUS). ▪ Establishment progressing according to plan: ✓ Planning initiated for the conversion of the fab into a MEMS fab. ✓ Product qualification activities initiated for MEMS devices to be manufactured at the fab. ✓ CFIUS filing submitted. Silex Interim Report July - Sept 2026 9
Page 11
0 156 256 255 255 250 0 0 0 154 154 154 219 254 0 233 233 233 Titles & Subtitles: Bai Jamjuree Medium (Headings) Text: Bai Jamjuree Medium Bold text: Bai Jamjuree Bold 191 255 255 Timeline, financial impact and investments 2026 Binding agreement signed. Silex gains access to premises and begins establishing MEMS operations. 2027 Continued establishment of MEMS operations. Product qualifications, knowledge transfer and implementation of operating model. 2028 Expected closing around year-end 2027. Silex gains ownership and scales up production. Investments funded through a combination of existing cash and funds available under current debt financing agreements. ~SEKm 1,000 Estimated capex 2026–2027, including purchase consideration ~SEKm 200 Estimated capex per year, 2028-2030 2029-2030 Objective to reach break-even for Silex U.S. Fab 2034 Objective to reach revenue and profitability levels comparable to the 2025 levels of Silex’s Swedish 200 mm fab 10Silex Interim Report July - Sept 2026
Page 12
Silex Interim Report July - Sept 2026 11 Financial summary Maria Engström, CFO
Page 13
Silex Interim Report July - Sept 2026 12 339 403 375 393 413 0 50 100 150 200 250 300 350 400 450 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Net sales Q3, SEKm ▪ Net sales of SEKm 413, up 21.7% YoY (22.0% currency- adjusted). ▪ Telecom sales increased by SEKm 74 or 68.3%. Life Science and Medical Technology grew by SEKm 30 or 67.9%. ▪ North American sales increased by SEKm 64 or 33.9%. ▪ Strong growth across both development and production projects, contributing SEKm 44 and SEKm 30, respectively. YoY +22% 1 360 1 385 1 426 1 510 1 584 1200 1250 1300 1350 1400 1450 1500 1550 1600 1650 Q3 25 LTM Q4 25 LTM Q1 26 LTM Q2 26 LTM Q3 26 LTM Net sales LTM, SEKm YoY +16% Q3 2026 Net sales
Page 14
402 368 409 487 526 30% 33% 0% 5% 10% 15% 20% 25% 30% 35% 0 100 200 300 400 500 600 Q3 25 LTM Q4 25 LTM Q1 26 LTM Q2 26 LTM Q3 26 LTM EBIT LTM, SEKm 108 117 128 134 14832% 36% 0% 5% 10% 15% 20% 25% 30% 35% 40% 0 20 40 60 80 100 120 140 160 180 200 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 EBIT, SEKm ▪ Strong EBIT of SEKm 148 (108) or EBIT margin 35.8 % (31.9 %). ▪ Adjusted EBIT1) of SEKm 148 (110) or EBIT margin 35.8 % (32.3 %). ▪ Strong profitability supported by higher sales and operating leverage. ▪ Positive foreign exchange impact of SEKm 12 (-7) driven by the SEK/USD. YoY +37% YoY +31% Silex Interim Report July - Sept 2026 1) Adjusted for non-recurring items of SEKm 0 (2). Non-recurring items relate to IPO-related consulting costs; the comparative period also included costs related to the change in ownership. Q3 2026 Profitability 13
Page 15
▪ Strong operating cash flow of SEKm 145 (30), supported by higher EBIT and improved working capital. ▪ Continued investments of SEKm 79 in capacity expansion at our Järfälla facility. ▪ SEKm 94 (USD 10m) deposit paid for the planned US fab acquisition. SEKm Q3 26 Q3 25 2026 LTM 2025 Cash flow from operating activities before changes in WC 153 137 564 536 Change in WC -8 -107 -18 -183 Cash flow from operating activities 145 30 546 353 Cash flow from investing activities -173 -71 -334 -195 Cash flow from financing activities -19 -295 932 -311 Cash flow for the period -47 -336 1,144 -153 Cash and cash equivalents at the end of the period 1,269 110 1,269 266 Silex Interim Report July - Sept 2026 14 Q3 2026 Cash flow and financial position
Page 16
Q3 2026 Financial results SEKm Q3 26 Q3 25 Change SEKm Change % Net sales 413 339 74 21.7% Other operating income 44 13 31 241.5% Total revenue 457 352 105 29.8% Operating expenses -310 -244 -66 26.8% Operating profit (EBIT) 148 108 40 36.6% Operating profit (EBIT) margin 35.8% 31.9% 3.9p.p Financial net 17 -2 19 - Earnings before tax 164 106 58 55.0% Income tax -34 -25 -9 40.0% Net profit 130 81 49 59.6% EPS 1) (SEK) 1.12 0.85 0.27 31.5% ▪ Net sales Increased with SEKm 74 increased or 21.7% (22.0% currency-adjusted), driven mainly by development projects, market area North America and the Telecom industry area. ▪ Operating expenses Increased with SEKm 66 which was due to higher business volumes and a larger workforce, reflecting continued business growth. ▪ EBIT Increased with SEKm 40 due to higher sales and operating leverage, supported by a positive net FX impact of SEK 12m (-7m). ▪ Adjusted EBIT margin 35.8% (32.3) which excludes non-recurring items2) of SEKm 0 (2). ▪ Net profit Increased with SEKm 49 generating an improved EPS. Silex Interim Report July - Sept 2026 151) After dillution 2) Non-recurring items relate to IPO consulting costs. The comparative period also included costs related to the change in ownership
Page 17
YTD 2026 Financial results ▪ Net sales Increased with SEKm 199 or 20.2% (28.0 currency- adjusted), driven by strong demand for development projects, growth in market North America and end markets Life Science and Medical Technology and Telecom. ▪ Operating expenses Increased with SEKm -92 reflecting continued business growth, with higher personnel and external costs. ▪ EBIT Increased with SEKm 159 as sales grew faster than costs, demonstrating operating leverage. EBIT included positive net FX impacts of SEKm 44 (-39). ▪ Adjusted EBIT margin 35.2% (27.0%) which excludes non-recurring items2) of SEKm 7 (14). ▪ Net profit Increased with SEKm 158 and thus generating an improved EPS. Silex Interim Report July - Sept 2026 16 SEKm YTD 26 YTD 25 Change SEKm Change Net sales 1 181 982 199 20.2% Other operating income 94 41 53 127.5% Total revenue 1 275 1 024 251 24.6% Operating expenses -865 -773 -92 12.0% Operating profit (EBIT) 410 251 159 63.2% Operating profit (EBIT) margin 34.7% 25.5% 9.1pp Financial net 18 -18 36 - Earnings before tax 427 233 194 83.1% Income tax -90 -54 -36 66.4% Net profit 337 179 158 88.2% EPS 1) (SEK) 3.05 1.98 1.07 54.2% 1) After dillution 2) Non-recurring items relate to IPO consulting costs. The comparative period also included costs related to the change in ownership
Page 18
FINANCIAL TARGETS CURRENT PERFORMANCE LTM SEKb 2.5 by 2030 SEKm 1 584 >30% (medium term) 33.2% <2X EBITDA -1.5X NET SALES EBIT MARGIN NET DEBT/EBITDA Financial targets Current performance Silex Interim Report July - Sept 2026 17 * Targets does not include U.S fab
Page 19
0 156 256 255 255 250 0 0 0 154 154 154 219 254 0 233 233 233 Titles & Subtitles: Bai Jamjuree Medium (Headings) Text: Bai Jamjuree Medium Bold text: Bai Jamjuree Bold 191 255 255 Financial calendar Silex Interim Report July - Sept 2026 18 Maria Engström CFO +46 8 580 249 00 ir@silex.se Year-end Report 2026 18 February 2027 Annual Report 2026 24 March 2027 Interim Report January – March 2027 28 April 2027 Annual General Meeting 2027 25 May 2027 Interim Report April – June 2027 15 July 2027 Interim Report July – September 2027 21 October 2027
Page 20
Silex Interim Report July - Sept 2026 19 Q&A